ES2922009T3 - Variantes de beta-lactamasa - Google Patents

Variantes de beta-lactamasa Download PDF

Info

Publication number
ES2922009T3
ES2922009T3 ES17706743T ES17706743T ES2922009T3 ES 2922009 T3 ES2922009 T3 ES 2922009T3 ES 17706743 T ES17706743 T ES 17706743T ES 17706743 T ES17706743 T ES 17706743T ES 2922009 T3 ES2922009 T3 ES 2922009T3
Authority
ES
Spain
Prior art keywords
polypeptide
val
ala
seq
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17706743T
Other languages
English (en)
Spanish (es)
Inventor
Gunzburg Jean De
Jean-Denis Docquier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Da Volterra SAS
Bioaster
Original Assignee
Da Volterra SAS
Bioaster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra SAS, Bioaster filed Critical Da Volterra SAS
Application granted granted Critical
Publication of ES2922009T3 publication Critical patent/ES2922009T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES17706743T 2016-02-23 2017-02-22 Variantes de beta-lactamasa Active ES2922009T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305209 2016-02-23
PCT/EP2017/053986 WO2017144496A1 (en) 2016-02-23 2017-02-22 Beta-lactamase variants

Publications (1)

Publication Number Publication Date
ES2922009T3 true ES2922009T3 (es) 2022-09-06

Family

ID=55521650

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17706743T Active ES2922009T3 (es) 2016-02-23 2017-02-22 Variantes de beta-lactamasa

Country Status (11)

Country Link
US (1) US10982205B2 (pt)
EP (1) EP3420078B1 (pt)
JP (1) JP6845258B6 (pt)
KR (1) KR20180110032A (pt)
CN (1) CN108699545A (pt)
BR (1) BR112018016889A2 (pt)
CA (1) CA3013166A1 (pt)
ES (1) ES2922009T3 (pt)
PL (1) PL3420078T3 (pt)
PT (1) PT3420078T (pt)
WO (1) WO2017144496A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004319A (es) * 2017-10-25 2020-10-12 Da Volterra Variantes de beta-lactamasas.
WO2020185861A1 (en) * 2019-03-11 2020-09-17 Regents Of The University Of Minnesota Proteins and methods for disrupting bacterial communication

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE4422198C2 (de) 1994-06-24 1997-08-28 Audi Ag Verfahren zum Steuern der elektrischen Beheizung eines Katalysators
NZ330940A (en) 1997-07-24 2000-02-28 F Production of consensus phytases from fungal origin using computer programmes
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FI20105572A0 (fi) * 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP2407433A1 (en) 2010-07-15 2012-01-18 Da Volterra Methods for the inactivation of antibiotics
US9551020B2 (en) * 2011-04-21 2017-01-24 Biomerieux, Inc. Method of detecting at least one mechanism of resistance to carbapenems by mass spectrometry
CN102757950A (zh) * 2011-04-25 2012-10-31 天津市国际生物医药联合研究院 超级细菌新德里金属依赖型β-内酰胺酶NDM-1的表达纯化及β-内酰胺酶NDM-1的晶体结构
US9290754B2 (en) * 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy

Also Published As

Publication number Publication date
CN108699545A (zh) 2018-10-23
WO2017144496A1 (en) 2017-08-31
EP3420078B1 (en) 2022-05-25
US20190062719A1 (en) 2019-02-28
PL3420078T3 (pl) 2022-09-19
US10982205B2 (en) 2021-04-20
BR112018016889A2 (pt) 2019-02-12
EP3420078A1 (en) 2019-01-02
JP6845258B2 (ja) 2021-03-17
PT3420078T (pt) 2022-07-13
JP2019511926A (ja) 2019-05-09
CA3013166A1 (en) 2017-08-31
KR20180110032A (ko) 2018-10-08
JP6845258B6 (ja) 2021-04-28

Similar Documents

Publication Publication Date Title
KR20180029953A (ko) 세포 또는 유기체의 게놈으로의 ＤＮＡ 서열의 표적화 혼입을 위한 Ｃａｓ 9 레트로바이러스 인테그라제 시스템 및 Ｃａｓ 9 재조합효소 시스템
US8236544B2 (en) Methods of improving the introduction of DNA into bacterial cells
KR20140117433A (ko) 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신
KR20120041073A (ko) Ｏ-포스포세린 설피드릴라제 변이체
CN111172129B (zh) 一种提高热稳定、扩增均一性和扩增效率的Phi29 DNA聚合酶突变体及其应用
ES2922009T3 (es) Variantes de beta-lactamasa
Pilehchian et al. Fusion of Clostridium perfringens type D and B epsilon and beta toxin genes and it’s cloning in E. coli
US20220356459A1 (en) Beta-lactamase variants
KR20140092835A (ko) 히단토이나제의 돌연변이체
EP3013949B1 (en) Codon modified amylase from bacillus akibai
US10988749B2 (en) Beta-lactamase variants
KR101634078B1 (ko) 봉입체 형성 단백질의 제조방법
JP6938482B2 (ja) 調節可能なリボソーム翻訳速度のための組成物および使用法
Patin et al. Unusual substrate specificity of the peptidoglycan MurE ligase from Erysipelothrix rhusiopathiae
EP3186379B1 (en) E. coli-based production of beta-lactamase
KR101891234B1 (ko) 신규 프로테아제
Novikov et al. The highly efficient expression of the aspartase gene (L-aspartate ammonia-lyase) in Escherichia coli cells
Meier et al. Complete DNA sequence of the atp operon of the sodium-dependent F1Fo ATP synthase from Ilyobacter tartaricus and identification of the encoded subunits
KR101582655B1 (ko) 광활성 메티오닌 모사체 표지 단백질 생합성을 위한 메티오닐 tRNA 합성효소 변이체
Baek et al. Overexpression of Arylsulfate Sulfotransferase as Fusion Protein with GlutathioneS-Transferase
KR20150136884A (ko) 유기인 신경작용제 분해효소의 변이체 및 이의 제조방법
KR20150044760A (ko) 극지세균 유래의 저온성 리파아제와 그 변이체 및 그의 용도